NICE GLP-1 Guidance for Mounjaro: What It Means for You (October 2026)

01 · The core answer

What does NICE say about GLP-1 medicines and Mounjaro?

NICE recommends Mounjaro on the NHS for a defined group of adults: Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶

The detail of who is offered treatment first, and when, is decided locally and in stages. Our guide to NICE guidelines on GLP-1 and weight loss goes deeper on the guidance itself, and the NICE tirzepatide appraisal explains how the decision was framed.

NICE has one decision covering tirzepatide for overweight and obesity and another covering tirzepatide for type 2 diabetes.⁴⁸ They have different purposes, and a person reading one should not assume it applies to the other.

02 · What to decide

The two decisions most readers face

The first decision is whether you appear to meet the NICE group for the NHS. If you are in a higher-need group, speak to your GP, because primary-care rollout has started and local services differ. Ask directly whether tirzepatide is being offered in your area yet.

The second decision is what to do if you do not meet the threshold, or you do but are waiting. Because the rollout is expected to take years, many people who meet the licensed criteria choose regulated private treatment rather than waiting. That is a personal choice, and a prescriber will still assess whether the medicine is suitable for you.

• You may suit the NHS route if your BMI and health conditions place you in a group being prioritised locally.
• You may suit private care if you meet the licensed criteria but are not yet being offered NHS treatment.
• You may suit neither if a prescriber decides the medicine is not right for you. Unsuitable orders are refunded automatically.

03 · Next step

If you want to look at private treatment

If NHS access is not available to you yet, our weight loss clinic explains the wider options, and the Mounjaro pen page shows live prices and starts the free consultation. Your first 2.5mg pen costs £129.99 with code FIRST40, against a standard price of £169.99. Every later order is £25 off the standard price. All six doses are in stock.

Mounjaro is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber. It is used alongside a reduced-calorie diet and increased physical activity. Individual results vary.

Related guides: Agonisti glp 1 and Ozempil glp-1 and Wat is glp-1.

04 · What NICE does

What NICE does and does not decide

NICE stands for the National Institute for Health and Care Excellence. It reviews evidence and cost-effectiveness, then recommends whether the NHS in England should fund a treatment and for which patients. It does not license medicines. Licensing is a separate step, and tirzepatide already holds a UK licence for weight management in adults and for type 2 diabetes.

A licence says a medicine is safe and effective enough to be sold for a stated use. A NICE recommendation says the NHS should pay for it for a defined group. A medicine can be licensed for a wide group while the NHS funds it for a narrower, higher-need group first. That is exactly the situation with Mounjaro.

NICE publishes separate documents for separate uses. One is the guidance on tirzepatide for managing overweight and obesity, which includes a practical prescribing guide.⁴ Another covers tirzepatide for treating type 2 diabetes.⁸ If your interest is weight management, the first is the relevant one. If you have diabetes, your diabetes team will follow the second and the wider diabetes pathway.

The recommendation wording, thresholds and phasing are set by NICE and NHS England and can be refined over time. The NHS England rollout guidance is the best place to check current local arrangements.⁶

Always read the original guidance, or ask your GP or specialist how it applies to you personally.

Your own prescriber considers your health history, other medicines and goals.

05 · NHS eligibility

NHS eligibility and the phased rollout

NHS eligibility for Mounjaro follows NICE, but access is being introduced in stages. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶

In plain terms, being inside the NICE group is necessary but may not be sufficient for treatment right now. The first people offered the medicine are those with the greatest clinical need. Over the following years the group should widen. Full rollout is expected to take years.

People often ask who is eligible on the NHS in 2026. The honest answer is that it depends on where you are in the phased order and on how your local service is organised. Your GP practice or integrated care board is the right place to ask, because they know what is currently being offered locally.

If you want to prepare for that conversation, it helps to know your BMI in kg/m² and to be able to list any weight-related health conditions you have been diagnosed with. Do not guess at which conditions qualify.

NHS England has published rollout guidance, and the NHS website has a patient-facing page on tirzepatide.⁵ Both are worth reading before you speak to your GP.

Wegovy is a different medicine with its own route. NHS access to Wegovy runs through specialist weight-management services; ask your GP.

If you are told you are not yet eligible, that is not a judgement that you do not need support. It reflects the rollout order. Ask what other help is available, such as lifestyle programmes, and ask when you might be reviewed again. Keep a note of the answer so you can follow up. You can also read about how the NICE weight-loss guidance is structured.

06 · How tirzepatide works

How tirzepatide differs from other GLP-1 medicines

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1.¹ Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin. In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.

This dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide (Wegovy/Ozempic). When NICE and others talk about GLP-1 receptor agonists, they usually mean the single-action group. Tirzepatide is often named alongside them in guidance because it overlaps in use, even though its mechanism is broader.

Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. In the UK it is licensed for weight management in adults and for type 2 diabetes. It comes as a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹

Everyone starts Mounjaro on 2.5mg once a week, and the dose can step up after at least 4 weeks on each dose, up to a maximum of 15mg weekly, depending on how you respond and tolerate it. A prescriber reviews you along the way and decides whether to go up, stay or stop.

Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears.¹ This is relevant if you stop, switch or plan a pregnancy, and it is a topic to discuss with your prescriber rather than manage alone. Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive.

Because the mechanism is hormonal and affects digestion, common side effects tend to be digestive. The most common, affecting more than 1 in 10 people, are nausea, diarrhoea, vomiting, constipation and abdominal discomfort, and for most people they ease within days to a few weeks as the body adjusts. Anything new or worrying should be raised with your prescriber and reported through the Yellow Card scheme.¹⁹

07 · What trials show

What the main trial showed

The headline evidence for Mounjaro in weight management comes from the SURMOUNT-1 trial. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.²

These are trial averages. Individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them. Trial averages do not predict your own result, and a trial population is not the same as every person who will use the medicine.

The trial also reported how many people reached particular thresholds. At 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight. Half of participants on 10mg and 57% on 15mg lost at least 20% of their body weight.²

Why does this matter for NICE? Appraisals weigh benefit against cost and look at evidence like this.

It is worth being careful when comparing medicines. Different trials enrolled different people, ran for different periods and used different designs. Only a head-to-head trial supports a direct comparison, so do not read one trial's numbers against another's as if they were a contest.

For a worked example of what a percentage means, someone starting at 100 kg who matched the 20.9% average on 15mg would lose about 21 kg. That is arithmetic on a trial average, not a forecast. Many people lose less, some lose more, and a prescriber will talk through realistic expectations with you.

Finally, trial results describe people who kept taking the medicine alongside lifestyle support. In SURMOUNT-4, people who stopped tirzepatide after 36 weeks regained on average 14% of body weight over the following year, so stopping should always be planned with your prescriber.

08 · NHS or private

NHS or private: how the routes compare

The NHS and private routes use the same licensed medicine, but they differ in who qualifies, how long you wait and what you pay. The NHS route is free at the point of use for those who qualify under the phased rollout. The private route is open to adults who meet the licensed criteria and pass a prescriber's suitability review.⁴

Waiting is the main reason people choose private care. Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.⁶ That is a fair description of the trade-off, and neither route is the wrong choice in principle.

If you are in a higher-need group, check the NHS route first, since it may cost you less. If you are told you are not yet eligible or there is a wait, private care is a legitimate alternative, provided it is properly regulated. Our registration is GPhC 9012878, and you can verify it on the GPhC register.¹²

Check any provider carefully. A genuine service requires a consultation and a prescription. Treat anyone offering to supply without a consultation or prescription as unsafe, and be wary of counterfeit pens sold outside regulated channels. The MHRA publishes counterfeit medicine alerts and runs the Yellow Card scheme for reporting problems.⁷

Switching between routes is possible in principle, for example if you start privately and later become eligible on the NHS. Speak to your GP and your prescriber so that your records and treatment plan stay consistent.

09 · Safety and suitability

Who should be cautious with GLP-1 medicines

Mounjaro is not suitable for everyone. You should not take it if you are allergic to tirzepatide or any of its ingredients, and it should not be used during pregnancy or while trying to conceive. Your prescriber will take extra care, or may recommend against treatment, if you have a history of pancreatitis, severe gut or digestive disease, diabetic retinopathy, or gallbladder problems. Mounjaro should be stopped at least one month before trying to conceive.

That is why an honest consultation matters. Tell the prescriber about your health history, every medicine you take and any pregnancy plans. The review is carried out by a GPhC-registered prescriber, not a scoring script, and if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.

Two specific interactions are worth knowing. Mounjaro slows stomach emptying, which can reduce how well oral contraceptive pills are absorbed. The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹ MHRA guidance covers contraception with GLP-1 and GIP medicines, so ask your prescriber what applies to you.⁷ If you take insulin or a sulfonylurea, doses may need adjusting because of the risk of low blood sugar, so your diabetes team should be involved.

Attend your monthly reviews and report anything new or worrying to your prescriber. You can also report suspected side effects through the Yellow Card scheme.¹⁹ Serious side effects are uncommon but need urgent attention. Seek immediate medical help for severe, persistent stomach pain that may spread to your back, with or without vomiting, pain in the upper right abdomen, fever or yellowing of skin or eyes, or signs of a severe allergic reaction.

Regulators have looked specifically at whether GLP-1 medicines are linked to low mood or suicidal thoughts: the EMA's safety committee reviewed the evidence and concluded in 2024 that it does not support a causal link, and the MHRA keeps this under continuous review.¹⁷ Tell your prescriber about any change in your mood, and seek help promptly if your mood drops or you have distressing thoughts during treatment.

If you have thoughts of harming yourself or ending your life, get help straight away. Call 999 or go to A&E if you are in immediate danger. In England you can call NHS 111 and choose the mental health option, any time. You can also call Samaritans free on 116 123, day or night. Tell your prescriber about any change in your mood while taking Mounjaro.

On lifestyle, the medicine is used alongside a reduced-calorie diet and increased physical activity. If you are unsure what to avoid, ask your prescriber, who can tailor advice to you. Side-effect support is part of our aftercare.

10 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

11 · Cost and ordering

What private treatment costs and how ordering works

Private Mounjaro is priced per monthly pen, and the live figures are on the Mounjaro pen page. Your first 2.5mg pen costs £129.99 with code FIRST40, against a standard price of £169.99. A new customer's first order at any dose is £40 less. Every later order is £25 off the standard price (code DOSE25). Prices were checked 10 October 2026.

Planning ahead helps. If you step up after 4 weeks on each dose, your first four pens (2.5mg to 10mg) cost £959.96 at standard prices, before discounts. A first year of 13 pens costs £2,711.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg, again at standard prices. If you settle at another strength, the monthly prices are £279.99 at 7.5mg, £290.99 at 10mg and £319.99 at 12.5mg.

Across the UK pharmacies we track, the cheapest and dearest Mounjaro pen prices were £143.96 and £339.00 when we last checked on 10 October 2026. Provider prices differ, so compare the whole cost over time rather than a single headline figure.

Ordering has four steps:

• Free online consultation: a short health questionnaire, no charge and no obligation.
• Prescriber review: a GPhC-registered prescriber reviews it. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.
• Dispensing and dispatch: dispensed by our registered pharmacy, with same-day dispatch when ordered by 3pm.
• Delivery: free next-day tracked delivery in temperature-controlled, discreet packaging. Saturday delivery is £14.99.

The consultation is free, the price shown is the price paid, and there are no hidden fees. We supply genuine KwikPens through official LillyDirect supply, and needles, a sharps bin and injection guidance come with every order. You can pay by Visa or Mastercard, Klarna or pay-monthly options, with no subscription. Repeat orders re-check suitability, and nothing ships automatically.

Support is available Monday to Friday, 9am to 5pm, by email at support@everydaymeds.co.uk, account chat or phone on 0333 207 0413. Our free GLPTrackr app can help you track your journey. If you want broader context first, start with the weight loss clinic overview.